About this Webinar:
High Mobility Group A (HMGA) proteins are essential non-histone chromatin factors that significantly influence chromatin architecture and gene regulation. With their pivotal roles in cellular differentiation, proliferation, and tumor progression, HMGA proteins serve as key players in both normal cellular functions and disease mechanisms.
Recent studies have identified the embryonic isoform of GATA6 as a downstream target of HMGA2, currently under clinical trials for early lung cancer detection. Additionally, Let-7d, a negative regulator of HMGAs, plays a crucial role in nuclear gene suppression and chromatin organization through the formation of the MiCEE complex. Disruption of this complex has been linked to enhanced fibrosis progression, while its reassembly via EP300 inhibition offers a promising therapeutic strategy to halt fibrosis progression. Furthermore, HMGA proteins facilitate the deposition and phosphorylation of H2AX, a key modification essential for transcriptional activation and chromatin remodeling.
This webinar will delve into these groundbreaking discoveries, highlighting over 15 years of HMGA research. It will explore their clinical implications, and unveil innovative approaches to tackle unanswered questions in chromatin biology and disease management. Join us for an engaging discussion on the future of HMGA proteins as therapeutic targets for cancer, fibrosis-related disorders, and beyond.
A recording of the webinar will be shared to all registrants.
Participants can request a webinar certificate by contacting Marketing@medchemexpress.com